Boehringer Ingelheim break ground on $217 million Fremont facility

pharmafile | August 1, 2017 | News story | Manufacturing and Production Boehringer Ingelheim, biotech, drugs, pharma, pharmaceutical 

Boehringer Ingelheim announced that it had broken ground on its planned $217 million upgrade and expansion of its existing Fermont manufacturing facility. The investment is expected to create a further 300 jobs to the city of Fremont, just south of San Francisco.

The facility produces biologics and biosimilars, with a focus on oncology, rheumatology and immunology. Should the expansion be carried out as planned, the production capability of the plant will be boosted by a third.

The facility currently covers 300,000 square feet and includes development labs, a pilot plant and large-scale bioreactors. The company had acquired the facility from Amgen, back in 2011, as part of a concerted effort to improve its contract biologics production.

“The Bay Area is the largest biotech cluster in the world. We are happy to have made Fremont our home and are grateful for the support we have received from the community and the State of California,” said Jens Vogel, President and CEO of Boehringer Ingelheim Fremont, Inc. “We have made a commitment to the region and are excited to continue to invest in the Bay Area and expand our workforce to help increase patient access to high-quality medicines.”

For its part of the commitment, the state provided the company with $25.5 million in two separate tax credits from the state – the largest award given to a pharmaceutical company. The facility is one of a global network of such manufacturing plants, that includes further locations in Germany, Austria and China.

Ben Hargreaves

Related Content

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content